GlassScriptPhysician profile
Vandana N Setia
NPI 1114958675
$818.90
in general payments reported to CMS, 2019-2025
15 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.11 · 2023: $55.25 · 2024: $323 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $805.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $270.64 | 2023-2025 | |
| Lilly USA, LLC | $108.29 | 2024-2025 | Zepbound, Mounjaro, Kisunla |
| Novo Nordisk INC | $99.22 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.14 | 2024-2025 | Ofev, Jardiance |
| Glaxosmithkline, LLC. | $46.78 | 2023-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $33.19 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Teva Pharmaceuticals USA, INC. | $29.10 | 2019-2025 | Austedo Xr |
| Sanofi Pasteur INC. | $27.17 | 2025 | |
| Exact Sciences Corporation | $25.38 | 2025 | The Cologuard Plus Collection Kit |
| Dexcom, INC. | $21.99 | 2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $21.31 | 2025 | |
| Amgen INC. | $20.06 | 2025 | Repatha, Otezla |
| Esperion Therapeutics, INC. | $18.86 | 2024 | Nexletol |
| Abbvie INC. | $15.55 | 2024 | |
| Astellas Pharma US INC | $15.22 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vandana Setia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.